A Wall Street Journal story featured two former Medtronic employees who alleged that the medical device maker engaged in off-label marketing of bilary stents for uses not approved by the Food and Drug Administration. The whistleblowers filed a lawsuit under the federal False Claims Act and Hagens Berman is representing them in court. You can read the full article here.